ArticleFrontiers in pharmacology2026
The application of low-dose rivaroxaban in elderly patients with atrial fibrillation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal anticoagulation strategy for stroke prevention in very elderly patients (≥80 years) with non-valvular atrial fibrillation (NVAF) remains challenging due to the high risks of both thromboembolism and bleeding. This study aimed to evaluate the effectiveness and safety of low-dose rivaroxaban (10 mg) in this specific population. Methods: This single-center, real-world cohort study enrolled 1,005 patients aged ≥80 years with NVAF between January 2021 and December 2023. Patients were categorized into three groups based on their antithrombotic regimen: a non-anticoagulation group (n = 177), a low-dose rivaroxaban group (10 mg, n = 168), and a conventional anticoagulation group (n = 660). The primary efficacy outcome was stroke, and the primary safety outcome was major bleeding. Outcomes were analyzed using multivariable Cox regression models and competing risk models to account for death as a competing event where appropriate. Results: Compared with no anticoagulation, low-dose rivaroxaban was associated with significantly lower risks of stroke (hazard ratio (HR) 0.20, 95% confidence interval (CI) 0.05-0.78; P = 0.0201), all-cause mortality (HR 0.28, 95% CI 0.13-0.60; P = 0.0012), and cardiac death (HR 0.31, 95% CI 0.17-0.81; P = 0.0170), with efficacy comparable to conventional anticoagulation. Direct comparison showed no significant differences in efficacy outcomes between the low-dose and conventional anticoagulation groups. Moreover, the risk of major bleeding was numerically lower with low-dose rivaroxaban than with conventional anticoagulation (HR 2.01 for conventional vs. low-dose, 95% CI 0.93-4.12; P = 0.0856). Conclusion: In very elderly patients (≥80 years) with NVAF, low-dose rivaroxaban (10 mg) was associated with similar effectiveness to conventional anticoagulation in preventing stroke and reducing mortality, while showing a potential safety advantage with a numerically lower risk of major bleeding. These findings support the use of low-dose rivaroxaban as a favorable individualized antithrombotic strategy for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.